Faron Pharmaceuticals Oy (FARN.L)

GBp 175.0

(2.94%)

Market Cap (In GBp)

183.09 Million

Revenue (In GBp)

-

Net Income (In GBp)

-30.94 Million

Avg. Volume

59.05 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
85.0-324.0
PE
-
EPS
-
Beta Value
0.329
ISIN
FI4000153309
CUSIP
X2382W107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Juho Markku Jalkanen M.D., MSc, Ph.D.
Employee Count
-
Website
https://www.faron.com
Ipo Date
2015-11-17
Details
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.